Janus Kinase Inhibitor
Oral zasocitinib presents high potential as new psoriasis treatment
Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.
Etiopathogenesis
Cardiovascular risk assessment recommended before use of small-molecule drugs in IBD
Although evidence suggests the risk for cardiovascular events with small-molecule drugs is low in patients with inflammatory bowel disease, experts advise screening for risk factors and stratification before initiation of therapy.
Kinase Inhibitors
Biologics Targeting Interleukin-17
Axial Spondyloarthritis and Ankylosing Spondylitis
Oral Systemic Therapy
Topical Therapy
Upadacitinib’s risk-benefit profile in rheumatoid arthritis ‘favorable’ through 5 years
The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.
JAK, IL-6 inhibition most effective targeted therapies for VEXAS syndrome
The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.